| Autor: |
Jetté Pomerleau V; Department of Medicine, University of Montreal Departments of †Neurology & Neurosurgery ‡Psychiatry, McGill University Health Centre and Montreal Neurological Hospital and Institute, McGill University; Montreal, Quebec, Canada., Dubeau F, Ducharme S |
| Jazyk: |
angličtina |
| Zdroj: |
Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology [Cogn Behav Neurol] 2017 Jun; Vol. 30 (2), pp. 73-76. |
| DOI: |
10.1097/WNN.0000000000000127 |
| Abstrakt: |
Since the middle of the 19th century, both neurologists and psychiatrists have linked psychosis and epilepsy. Clozapine, the most effective antipsychotic drug, alters electroencephalographic activity and carries a significant risk of causing seizures. Unfortunately, this risk limits the drug's potential use in treating pharmacoresistant psychosis in patients with epilepsy. We present a unique case in which we used clozapine successfully as a last resort treatment for chronic interictal psychosis in a 43-year-old woman with severe pharmacoresistant epilepsy and recurrent status epilepticus. Her psychotic symptoms improved markedly without an increase in the frequency of seizures despite gradual titration of the clozapine dose up to 300 mg daily. Her response demonstrates that, properly monitored, clozapine can be an effective treatment for psychosis even in patients with daily seizures. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
